Mr. Land has more than 30 years of experience in financial positions where he had responsibility for the accounting, treasury, tax, investor relations, information technology and strategic planning functions. From 2006 to 2007, Mr. Land served as Executive Vice President and Chief Financial Officer of Medcenter Solutions, Inc., a global pharmaceutical marketing company specializing in online solutions. From 2005 until 2006, Mr. Land served as Senior Vice President and Chief Financial Officer of Orchid Cellmark Inc., a DNA testing service provider that generates genetic profile information by analyzing an organism's unique genetic identity.
From 1997 until 2005, Mr. Land was Senior Vice President and Chief Financial Officer of NASDAQ-traded Genencor International, Inc., a global diversified genomics and proteomics company that went public during his tenure and was acquired in a $1.2 billion transaction in 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for publicly traded West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions, including Vice President-Corporate Controller. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years.
Mr. Land is a Certified Public Accountant and has a BBA degree in accounting and finance from Temple University. Mr. Land serves on the board of Anika Therapeutics, Inc., as Chairperson of the Audit Committee.
He is married and will relocate with his wife, Kathleen, to Southern California from his current home in the greater Philadelphia area.
Clarient combines innovative technologies with world class expertise to
assess and characterize cancer. Clarient's mission is to provide the
services, resources and critical information to improve the quality and
|SOURCE Clarient, Inc.|
Copyright©2008 PR Newswire.
All rights reserved